Clinical trials: MDS (Myelodysplastic Syndrome)
Acute Leukemia, Myelodysplasia
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
- Conditions
- Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
- Trial name
- NCT04202835
- Testing
- Cyclophosphamide, Anti-Thymocyte globulin (rabbit)
- Where
- 9 sites in Australia, Canada
- Volunteers
- 80 people
- Sponsor
- McMaster University
Hematologic Malignancy
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
This is a phase I study to evaluate the safety ,Tolerability, PK, PD, and preliminary efficacy of BC3402 Monotherapy in MDS or CMML, and explore the RP2D/MTD dose.
- Trial name
- NCT05690425
- Testing
- BC3402 Injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS)
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic…
- Trial name
- NCT07753148
- Testing
- REGN17235
- Where
- 2 sites in Belgium
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
This research is being done to evaluate effectiveness, safety, and tolerability of a study drug called momelotinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), MDS/MPN-not otherwise specified…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
- Trial name
- M-HArbOr (NCT07071155)
- Testing
- Momelotinib, Azacitidine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myelodysplastic Syndrome
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
This study will test the safety of giving you specialized white cells from your donor. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT00620633
- Testing
- WT1-sensitized T cells
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease, Leukemia
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002833
- Testing
- Filgrastim, Cladribine, Cyclosporine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
The purpose of this randomized, two-arm, open-label expansion phase study was to collect preliminary efficacy data of panobinostat at the recommended phase II dose (RPIID) level in combination with azacytidine (5-Aza) versus an…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00946647
- Testing
- Panobinostat (LBH589), 5-Azacytidine
- Where
- 38 sites in United States, Austria and 12 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
- Trial name
- NCT01461538
- Testing
- brentuximab vedotin
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Seagen Inc.
Leukemia, Myelodysplastic Syndromes
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory…
- Trial name
- NCT00003693
- Testing
- Dolastatin 10
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q.
- Trial name
- AZALE (NCT00923234)
- Testing
- Azacitidine, Lenalidomide
- Where
- 4 sites in Germany
- Sponsor
- Technische Universität Dresden
Paroxysmal Nocturnal Hemoglobinuria
Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.
- Trial name
- NCT01192399
- Testing
- Eculizumab
- Volunteers
- 29 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hematologic Neoplasm, Acute Leukemia
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
The primary objective of the study is to assess efficacy and safety of different prophylactic or therapeutic antithrombotic approaches in patients with hematologic neoplasms and platelet count <50 x109/L, including unfractionated…
- Conditions
- Hematologic Neoplasm, Acute Leukemia, Myelodysplastic Syndrome, Lymphoma
- Trial name
- NCT01855698
- Testing
- Observation
- Where
- 23 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Myelodysplastic Syndromes(MDS)
Collection of Samples From Patients With MDS
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
- Trial name
- NCT03072498
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- PersImmune, Inc
Leukemia, Myelodysplastic Syndromes
Decitabine in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic…
- Trial name
- NCT00003361
- Testing
- decitabine
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
- Trial name
- NCT01085656
- Testing
- OXi4503
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Paroxysmal Nocturnal Haemoglobinuria
Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal haemaoglobinuria (PNH) is a rare disease which results in breakdown of the red blood cells and bone marrow failure. It is associated with an increased risk of blood clots.
- Trial name
- NCT01020188
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College Hospital NHS Trust
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative…
- Conditions
- Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT05515029
- Testing
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- Where
- Russia
- Volunteers
- 56 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
MDS
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Comparison of survival in patients with or without a matched donor at 36 months
- Trial name
- NCT02757989
- Testing
- transplantation
- Where
- 37 sites in France
- Volunteers
- 79 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q)
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT02666950
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.